ID   UB2R1_HUMAN             Reviewed;         236 AA.
AC   P49427; A8K689;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   10-MAY-2017, entry version 166.
DE   RecName: Full=Ubiquitin-conjugating enzyme E2 R1;
DE            EC=2.3.2.23 {ECO:0000269|PubMed:12037680, ECO:0000269|PubMed:17698585, ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:20347421};
DE   AltName: Full=(E3-independent) E2 ubiquitin-conjugating enzyme R1;
DE            EC=2.3.2.24 {ECO:0000269|PubMed:17588522};
DE   AltName: Full=E2 ubiquitin-conjugating enzyme R1;
DE   AltName: Full=Ubiquitin-conjugating enzyme E2-32 kDa complementing;
DE   AltName: Full=Ubiquitin-conjugating enzyme E2-CDC34;
DE   AltName: Full=Ubiquitin-protein ligase R1;
GN   Name=CDC34; Synonyms=UBCH3, UBE2R1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8248134; DOI=10.1073/pnas.90.22.10484;
RA   Plon S.E., Leppig K.A., Do H.N., Groudine M.;
RT   "Cloning of the human homolog of the CDC34 cell cycle gene by
RT   complementation in yeast.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10484-10488(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT HIS-227.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, AND MUTAGENESIS OF CYS-93.
RX   PubMed=10329681; DOI=10.1074/jbc.274.21.14823;
RA   Gonen H., Bercovich B., Orian A., Carrano A., Takizawa C.,
RA   Yamanaka K., Pagano M., Iwai K., Ciechanover A.;
RT   "Identification of the ubiquitin carrier proteins, E2s, involved in
RT   signal-induced conjugation and subsequent degradation of
RT   IkappaBalpha.";
RL   J. Biol. Chem. 274:14823-14830(1999).
RN   [8]
RP   INTERACTION WITH ATF5 AND CREM, FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=10373550; DOI=10.1128/MCB.19.7.5001;
RA   Pati D., Meistrich M.L., Plon S.E.;
RT   "Human Cdc34 and Rad6B ubiquitin-conjugating enzymes target repressors
RT   of cyclic AMP-induced transcription for proteolysis.";
RL   Mol. Cell. Biol. 19:5001-5013(1999).
RN   [9]
RP   SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=10769200;
RA   Reymond F., Wirbelauer C., Krek W.;
RT   "Association of human ubiquitin-conjugating enzyme CDC34 with the
RT   mitotic spindle in anaphase.";
RL   J. Cell Sci. 113:1687-1694(2000).
RN   [10]
RP   FUNCTION.
RX   PubMed=10871850; DOI=10.1038/sj.onc.1203618;
RA   Charrasse S., Carena I., Brondani V., Klempnauer K.H., Ferrari S.;
RT   "Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement
RT   of the Cdc34-SCF(p45Skp2) pathway.";
RL   Oncogene 19:2986-2995(2000).
RN   [11]
RP   INTERACTION WITH SCF COMPLEX.
RX   PubMed=10918611; DOI=10.1038/sj.onc.1203647;
RA   Strack P., Caligiuri M., Pelletier M., Boisclair M., Theodoras A.,
RA   Beer-Romero P., Glass S., Parsons T., Copeland R.A., Auger K.R.,
RA   Benfield P., Brizuela L., Rolfe M.;
RT   "SCF(beta-TRCP) and phosphorylation dependent ubiquitination of I
RT   kappa B alpha catalyzed by Ubc3 and Ubc4.";
RL   Oncogene 19:3529-3536(2000).
RN   [12]
RP   INTERACTION WITH CSNK2B, PHOSPHORYLATION AT SER-203; SER-222; SER-231;
RP   THR-233 AND SER-236, MUTAGENESIS OF SER-203; SER-222; SER-231; THR-233
RP   AND SER-236, AND SUBCELLULAR LOCATION.
RX   PubMed=11546811; DOI=10.1074/jbc.M106453200;
RA   Block K., Boyer T.G., Yew P.R.;
RT   "Phosphorylation of the human ubiquitin-conjugating enzyme, CDC34, by
RT   casein kinase 2.";
RL   J. Biol. Chem. 276:41049-41058(2001).
RN   [13]
RP   INTERACTION WITH HUMAN HERPESVIRUS 1 PROTEIN ICP0, AND ASSOCIATION
RP   WITH THE PROTEASOME.
RX   PubMed=11447293; DOI=10.1073/pnas.161283098;
RA   Van Sant C., Hagglund R., Lopez P., Roizman B.;
RT   "The infected cell protein 0 of herpes simplex virus 1 dynamically
RT   interacts with proteasomes, binds and activates the cdc34 E2
RT   ubiquitin-conjugating enzyme, and possesses in vitro E3 ubiquitin
RT   ligase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8815-8820(2001).
RN   [14]
RP   INTERACTION WITH SCF COMPLEX, FUNCTION, AND ENZYME REGULATION.
RX   PubMed=11675391; DOI=10.1074/jbc.M108008200;
RA   Wu K., Chen A., Tan P., Pan Z.Q.;
RT   "The Nedd8-conjugated ROC1-CUL1 core ubiquitin ligase utilizes Nedd8
RT   charged surface residues for efficient polyubiquitin chain assembly
RT   catalyzed by Cdc34.";
RL   J. Biol. Chem. 277:516-527(2002).
RN   [15]
RP   CATALYTIC ACTIVITY, FUNCTION, INTERACTION WITH BTRC, PHOSPHORYLATION
RP   AT SER-231, AND MUTAGENESIS OF CYS-93; LEU-97 AND SER-231.
RX   PubMed=12037680; DOI=10.1038/sj.onc.1205574;
RA   Semplici F., Meggio F., Pinna L.A., Oliviero S.;
RT   "CK2-dependent phosphorylation of the E2 ubiquitin conjugating enzyme
RT   UBC3B induces its interaction with beta-TrCP and enhances beta-catenin
RT   degradation.";
RL   Oncogene 21:3978-3987(2002).
RN   [16]
RP   INTERACTION WITH HUMAN HERPES VIRUS 1 PROTEIN ICP0, AND
RP   AUTOUBIQUITINATION.
RX   PubMed=11805320; DOI=10.1073/pnas.022531599;
RA   Hagglund R., Van Sant C., Lopez P., Roizman B.;
RT   "Herpes simplex virus 1-infected cell protein 0 contains two E3
RT   ubiquitin ligase sites specific for different E2 ubiquitin-conjugating
RT   enzymes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:631-636(2002).
RN   [17]
RP   INTERACTION WITH HUMAN HERPES VIRUS 1 PROTEIN ICP0, AND
RP   AUTOUBIQUITINATION.
RX   PubMed=12060736; DOI=10.1073/pnas.122246999;
RA   Hagglund R., Roizman B.;
RT   "Characterization of the novel E3 ubiquitin ligase encoded in exon 3
RT   of herpes simplex virus-1-infected cell protein 0.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:7889-7894(2002).
RN   [18]
RP   FUNCTION.
RX   PubMed=15652359; DOI=10.1016/j.yexcr.2004.10.008;
RA   Butz N., Ruetz S., Natt F., Hall J., Weiler J., Mestan J., Ducarre M.,
RA   Grossenbacher R., Hauser P., Kempf D., Hofmann F.;
RT   "The human ubiquitin-conjugating enzyme Cdc34 controls cellular
RT   proliferation through regulation of p27Kip1 protein levels.";
RL   Exp. Cell Res. 303:482-493(2005).
RN   [19]
RP   PHOSPHORYLATION AT SER-203; SER-222 AND SER-231, AND FUNCTION.
RX   PubMed=17461777; DOI=10.1042/BJ20061812;
RA   Sadowski M., Mawson A., Baker R., Sarcevic B.;
RT   "Cdc34 C-terminal tail phosphorylation regulates Skp1/cullin/F-box
RT   (SCF)-mediated ubiquitination and cell cycle progression.";
RL   Biochem. J. 405:569-581(2007).
RN   [20]
RP   CATALYTIC ACTIVITY AS E3-INDEPENDENT E2 UBIQUITIN-CONJUGATING ENZYME.
RX   PubMed=17588522; DOI=10.1016/j.molcel.2007.05.014;
RA   Hoeller D., Hecker C.M., Wagner S., Rogov V., Doetsch V., Dikic I.;
RT   "E3-independent monoubiquitination of ubiquitin-binding proteins.";
RL   Mol. Cell 26:891-898(2007).
RN   [21]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASN-85; TYR-87;
RP   SER-95; ASP-102; ASP-103; GLU-108; GLU-112; SER-138; ASP-143; MET-147;
RP   ARG-149; LYS-150 AND GLU-153.
RX   PubMed=17698585; DOI=10.1128/MCB.00812-07;
RA   Gazdoiu S., Yamoah K., Wu K., Pan Z.Q.;
RT   "Human Cdc34 employs distinct sites to coordinate attachment of
RT   ubiquitin to a substrate and assembly of polyubiquitin chains.";
RL   Mol. Cell. Biol. 27:7041-7052(2007).
RN   [22]
RP   INTERACTION WITH SCF COMPLEX.
RX   PubMed=18851830; DOI=10.1016/j.molcel.2008.08.021;
RA   Saha A., Deshaies R.J.;
RT   "Multimodal activation of the ubiquitin ligase SCF by Nedd8
RT   conjugation.";
RL   Mol. Cell 32:21-31(2008).
RN   [23]
RP   FUNCTION, INTERACTION WITH SCF COMPLEX, DOMAIN, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=19945379; DOI=10.1016/j.cell.2009.10.030;
RA   Kleiger G., Saha A., Lewis S., Kuhlman B., Deshaies R.J.;
RT   "Rapid E2-E3 assembly and disassembly enable processive ubiquitylation
RT   of cullin-RING ubiquitin ligase substrates.";
RL   Cell 139:957-968(2009).
RN   [24]
RP   IDENTIFICATION IN A UBIQUITIN LIGASE COMPLEX WITH HINT1 AND RBX1, AND
RP   FUNCTION.
RX   PubMed=19112177; DOI=10.1074/jbc.M804531200;
RA   Cen B., Li H., Weinstein I.B.;
RT   "Histidine triad nucleotide-binding protein 1 up-regulates cellular
RT   levels of p27KIP1 by targeting ScfSKP2 ubiquitin ligase and Src.";
RL   J. Biol. Chem. 284:5265-5276(2009).
RN   [25]
RP   INDUCTION, AND FUNCTION.
RX   PubMed=19126550; DOI=10.1074/jbc.C900002200;
RA   Legesse-Miller A., Elemento O., Pfau S.J., Forman J.J., Tavazoie S.,
RA   Coller H.A.;
RT   "let-7 Overexpression leads to an increased fraction of cells in G2/M,
RT   direct down-regulation of Cdc34, and stabilization of Wee1 kinase in
RT   primary fibroblasts.";
RL   J. Biol. Chem. 284:6605-6609(2009).
RN   [26]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20061386; DOI=10.1074/jbc.M109.089003;
RA   David Y., Ziv T., Admon A., Navon A.;
RT   "The E2 ubiquitin-conjugating enzymes direct polyubiquitination to
RT   preferred lysines.";
RL   J. Biol. Chem. 285:8595-8604(2010).
RN   [27]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20347421; DOI=10.1016/j.molcel.2010.02.025;
RA   Wu K., Kovacev J., Pan Z.Q.;
RT   "Priming and extending: a UbcH5/Cdc34 E2 handoff mechanism for
RT   polyubiquitination on a SCF substrate.";
RL   Mol. Cell 37:784-796(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 7-184.
RG   Structural genomics consortium (SGC);
RT   "Human ubiquitin-conjugating enzyme cdc34.";
RL   Submitted (FEB-2009) to the PDB data bank.
CC   -!- FUNCTION: Accepts ubiquitin from the E1 complex and catalyzes its
CC       covalent attachment to other proteins. In vitro catalyzes 'Lys-
CC       48'-linked polyubiquitination. Cooperates with the E2 UBCH5C and
CC       the SCF(FBXW11) E3 ligase complex for the polyubiquitination of
CC       NFKBIA leading to its subsequent proteasomal degradation. Performs
CC       ubiquitin chain elongation building ubiquitin chains from the
CC       UBE2D3-primed NFKBIA-linked ubiquitin. UBE2D3 acts as an initiator
CC       E2, priming the phosphorylated NFKBIA target at positions 'Lys-21'
CC       and/or 'Lys-22' with a monoubiquitin. Cooperates with the
CC       SCF(SKP2) E3 ligase complex to regulate cell proliferation through
CC       ubiquitination and degradation of MYBL2 and KIP1. Involved in
CC       ubiquitin conjugation and degradation of CREM isoform ICERIIgamma
CC       and ATF15 resulting in abrogation of ICERIIgamma- and ATF5-
CC       mediated repression of cAMP-induced transcription during both
CC       meiotic and mitotic cell cycles. Involved in the regulation of the
CC       cell cycle G2/M phase through its targeting of the WEE1 kinase for
CC       ubiquitination and degradation. Also involved in the degradation
CC       of beta-catenin. Is target of human herpes virus 1 protein ICP0,
CC       leading to ICP0-dependent dynamic interaction with proteasomes.
CC       {ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:10373550,
CC       ECO:0000269|PubMed:10871850, ECO:0000269|PubMed:11675391,
CC       ECO:0000269|PubMed:12037680, ECO:0000269|PubMed:15652359,
CC       ECO:0000269|PubMed:17461777, ECO:0000269|PubMed:17698585,
CC       ECO:0000269|PubMed:19112177, ECO:0000269|PubMed:19126550,
CC       ECO:0000269|PubMed:19945379, ECO:0000269|PubMed:20061386,
CC       ECO:0000269|PubMed:20347421}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E1 ubiquitin-activating
CC       enzyme]-L-cysteine + [E2 ubiquitin-conjugating enzyme]-L-cysteine
CC       = [E1 ubiquitin-activating enzyme]-L-cysteine + S-ubiquitinyl-[E2
CC       ubiquitin-conjugating enzyme]-L-cysteine. {ECO:0000255|PROSITE-
CC       ProRule:PRU00388, ECO:0000255|PROSITE-ProRule:PRU10133,
CC       ECO:0000269|PubMed:12037680, ECO:0000269|PubMed:17698585,
CC       ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:20347421}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E1 ubiquitin-activating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E1 ubiquitin-
CC       activating enzyme]-L-cysteine + N(6)-monoubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:17588522}.
CC   -!- ENZYME REGULATION: CDC34-catalyzed polyubiquitin chain assembly
CC       activity is stimulated by the conjugation of NEDD8 to the CUL1 SCF
CC       E3 ligase complex subunit. {ECO:0000269|PubMed:11675391}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.11 uM for beta-catenin-monoubiquin
CC         {ECO:0000269|PubMed:19945379};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000255|PROSITE-ProRule:PRU00388}.
CC   -!- SUBUNIT: Interacts with SCF (SKP1-CUL1-F-box protein) E3 ubiquitin
CC       ligase complex. Identified in a SCF (SKP1-CUL1-F-box protein) E3
CC       ubiquitin ligase complex together with HINT1 and RBX1. When cullin
CC       is neddylated, the interaction between the E2 and the SCF complex
CC       is strengthened. When phosphorylated, interacts with beta-TrCP
CC       (BTRC). Interacts with human herpes virus 1 protein ICP0 and
CC       associates with the proteasome for degradation. Interacts with
CC       casein kinase subunit CSNK2B. {ECO:0000269|PubMed:10373550,
CC       ECO:0000269|PubMed:10918611, ECO:0000269|PubMed:11447293,
CC       ECO:0000269|PubMed:11546811, ECO:0000269|PubMed:11675391,
CC       ECO:0000269|PubMed:11805320, ECO:0000269|PubMed:12037680,
CC       ECO:0000269|PubMed:12060736, ECO:0000269|PubMed:18851830,
CC       ECO:0000269|PubMed:19112177, ECO:0000269|PubMed:19945379}.
CC   -!- INTERACTION:
CC       Q13616:CUL1; NbExp=3; IntAct=EBI-975634, EBI-359390;
CC       O00560:SDCBP; NbExp=5; IntAct=EBI-975634, EBI-727004;
CC       Q8IUQ4:SIAH1; NbExp=3; IntAct=EBI-975634, EBI-747107;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=The phosphorylation
CC       of the C-terminal tail plays an important role in mediating
CC       nuclear localization. Colocalizes with beta-tubulin on mitotic
CC       spindles in anaphase.
CC   -!- TISSUE SPECIFICITY: Expressed in testes during spermatogenesis to
CC       regulate repression of cAMP-induced transcription.
CC       {ECO:0000269|PubMed:10373550}.
CC   -!- INDUCTION: Negatively regulated by the let-7 microRNA.
CC       {ECO:0000269|PubMed:19126550}.
CC   -!- DOMAIN: The C-terminal acidic tail is required for nuclear
CC       localization and is involved in the binding to SCF E3 ligase
CC       complexes, and more specifically with the CUL1 subunit.
CC       {ECO:0000269|PubMed:10769200, ECO:0000269|PubMed:19945379}.
CC   -!- PTM: Autoubiquitinated. Autoubiquitination is promoted by the
CC       human herpes virus 1 protein ICP0 and leads to degradation by the
CC       Ubiquitin-proteasomal pathway. {ECO:0000269|PubMed:11805320,
CC       ECO:0000269|PubMed:12060736}.
CC   -!- PTM: Phosphorylated by CK2. Phosphorylation of the C-terminal tail
CC       by CK2 controles the nuclear localization.
CC       {ECO:0000269|PubMed:11546811, ECO:0000269|PubMed:12037680,
CC       ECO:0000269|PubMed:17461777}.
CC   -!- SIMILARITY: Belongs to the ubiquitin-conjugating enzyme family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00388}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC37534.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdc34/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L22005; AAC37534.1; ALT_INIT; mRNA.
DR   EMBL; BT006659; AAP35305.1; -; mRNA.
DR   EMBL; AY650399; AAT46688.1; -; Genomic_DNA.
DR   EMBL; AK291554; BAF84243.1; -; mRNA.
DR   EMBL; CH471242; EAW61190.1; -; Genomic_DNA.
DR   EMBL; BC009850; AAH09850.1; -; mRNA.
DR   EMBL; BC018143; AAH18143.1; -; mRNA.
DR   EMBL; BC023979; AAH23979.1; -; mRNA.
DR   CCDS; CCDS12030.1; -.
DR   PIR; A49630; A49630.
DR   RefSeq; NP_004350.1; NM_004359.1.
DR   UniGene; Hs.514997; -.
DR   PDB; 2OB4; X-ray; 2.40 A; A=7-184.
DR   PDB; 3RZ3; X-ray; 2.30 A; A/B/C/D=7-184.
DR   PDB; 4MDK; X-ray; 2.61 A; A/B/C/D=7-184.
DR   PDBsum; 2OB4; -.
DR   PDBsum; 3RZ3; -.
DR   PDBsum; 4MDK; -.
DR   ProteinModelPortal; P49427; -.
DR   SMR; P49427; -.
DR   BioGrid; 107432; 58.
DR   DIP; DIP-37783N; -.
DR   IntAct; P49427; 18.
DR   MINT; MINT-238910; -.
DR   STRING; 9606.ENSP00000215574; -.
DR   iPTMnet; P49427; -.
DR   PhosphoSitePlus; P49427; -.
DR   BioMuta; CDC34; -.
DR   DMDM; 2507505; -.
DR   EPD; P49427; -.
DR   MaxQB; P49427; -.
DR   PaxDb; P49427; -.
DR   PeptideAtlas; P49427; -.
DR   PRIDE; P49427; -.
DR   DNASU; 997; -.
DR   Ensembl; ENST00000215574; ENSP00000215574; ENSG00000099804.
DR   GeneID; 997; -.
DR   KEGG; hsa:997; -.
DR   UCSC; uc002lov.4; human.
DR   CTD; 997; -.
DR   DisGeNET; 997; -.
DR   GeneCards; CDC34; -.
DR   HGNC; HGNC:1734; CDC34.
DR   HPA; CAB005109; -.
DR   HPA; CAB047311; -.
DR   HPA; HPA002382; -.
DR   MIM; 116948; gene.
DR   neXtProt; NX_P49427; -.
DR   OpenTargets; ENSG00000099804; -.
DR   PharmGKB; PA26265; -.
DR   eggNOG; KOG0425; Eukaryota.
DR   eggNOG; COG5078; LUCA.
DR   GeneTree; ENSGT00730000110436; -.
DR   HOGENOM; HOG000233454; -.
DR   HOVERGEN; HBG063308; -.
DR   InParanoid; P49427; -.
DR   KO; K02207; -.
DR   OMA; CFGEDED; -.
DR   OrthoDB; EOG091G0O9F; -.
DR   PhylomeDB; P49427; -.
DR   TreeFam; TF101107; -.
DR   BRENDA; 2.3.2.B6; 2681.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-8866652; Synthesis of active ubiquitin: roles of E1 and E2 enzymes.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; P49427; -.
DR   SIGNOR; P49427; -.
DR   UniPathway; UPA00143; -.
DR   EvolutionaryTrace; P49427; -.
DR   GeneWiki; CDC34; -.
DR   GenomeRNAi; 997; -.
DR   PRO; PR:P49427; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000099804; -.
DR   CleanEx; HS_CDC34; -.
DR   ExpressionAtlas; P49427; baseline and differential.
DR   Genevisible; P49427; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; NAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0061631; F:ubiquitin conjugating enzyme activity; IDA:MGI.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IBA:GO_Central.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0006464; P:cellular protein modification process; NAS:UniProtKB.
DR   GO; GO:0035458; P:cellular response to interferon-beta; IMP:UniProtKB.
DR   GO; GO:0006270; P:DNA replication initiation; NAS:UniProtKB.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; NAS:UniProtKB.
DR   GO; GO:0043951; P:negative regulation of cAMP-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0090261; P:positive regulation of inclusion body assembly; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0070848; P:response to growth factor; IEA:Ensembl.
DR   CDD; cd00195; UBCc; 1.
DR   Gene3D; 3.10.110.10; -; 1.
DR   InterPro; IPR000608; UBQ-conjugat_E2.
DR   InterPro; IPR023313; UBQ-conjugating_AS.
DR   InterPro; IPR016135; UBQ-conjugating_enzyme/RWD.
DR   Pfam; PF00179; UQ_con; 1.
DR   SUPFAM; SSF54495; SSF54495; 1.
DR   PROSITE; PS00183; UBIQUITIN_CONJUGAT_1; 1.
DR   PROSITE; PS50127; UBIQUITIN_CONJUGAT_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Complete proteome; Cytoplasm;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway.
FT   CHAIN         1    236       Ubiquitin-conjugating enzyme E2 R1.
FT                                /FTId=PRO_0000082451.
FT   REGION      190    236       SCF-binding.
FT   COMPBIAS    200    236       Asp/Glu-rich (acidic).
FT   ACT_SITE     93     93       Glycyl thioester intermediate.
FT   MOD_RES     203    203       Phosphoserine; by CK2.
FT                                {ECO:0000269|PubMed:11546811,
FT                                ECO:0000269|PubMed:17461777}.
FT   MOD_RES     222    222       Phosphoserine; by CK2.
FT                                {ECO:0000269|PubMed:11546811,
FT                                ECO:0000269|PubMed:17461777}.
FT   MOD_RES     231    231       Phosphoserine; by CK2.
FT                                {ECO:0000269|PubMed:11546811,
FT                                ECO:0000269|PubMed:12037680,
FT                                ECO:0000269|PubMed:17461777}.
FT   MOD_RES     233    233       Phosphothreonine; by CK2.
FT                                {ECO:0000269|PubMed:11546811}.
FT   MOD_RES     236    236       Phosphoserine; by CK2.
FT                                {ECO:0000269|PubMed:11546811}.
FT   VARIANT     227    227       D -> H (in dbSNP:rs16990650).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_021277.
FT   MUTAGEN      85     85       N->Q: Inhibits both mono and
FT                                polyubiquitination of NFKBIA.
FT                                {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN      87     87       Y->A: Decreases polyubiquitination of
FT                                NFKBIA. {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN      93     93       C->S,A: Loss of function.
FT                                {ECO:0000269|PubMed:10329681,
FT                                ECO:0000269|PubMed:12037680}.
FT   MUTAGEN      95     95       S->D: Inhibits both mono and
FT                                polyubiquitination of NFKBIA.
FT                                {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN      97     97       L->S: Loss of function.
FT                                {ECO:0000269|PubMed:12037680}.
FT   MUTAGEN     102    102       D->A: Inhibits polyubiquitination of
FT                                NFKBIA; when associated with A-103.
FT                                {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN     103    103       D->A: Inhibits polyubiquitination of
FT                                NFKBIA; when associated with A-102.
FT                                {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN     108    108       E->A: Inhibits both mono and
FT                                polyubiquitination of NFKBIA; when
FT                                associated with A-112.
FT                                {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN     112    112       E->A: Inhibits both mono
FT                                andpolyubiquitination of NFKBIA; when
FT                                associated with A-108.
FT                                {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN     138    138       S->A: Decreases monoubiquitination of
FT                                NFKBIA and inhibits polyubiquitination of
FT                                NFKBIA. {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN     143    143       D->A: Inhibits polyubiquitination of
FT                                NFKBIA; when associated with A-147; A-
FT                                149; A-150 and A-153.
FT                                {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN     147    147       M->A: Inhibits polyubiquitination of
FT                                NFKBIA; when associated with A-143; A-
FT                                149; A-150 and A-153.
FT                                {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN     149    149       R->A: Inhibits polyubiquitination of
FT                                NFKBIA; when associated with A-147; A-
FT                                147; A-150 and A-153.
FT                                {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN     150    150       K->A: Inhibits polyubiquitination of
FT                                NFKBIA; when associated with A-143; A-
FT                                147; A-149 and A-153.
FT                                {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN     153    153       E->A: Inhibits polyubiquitination of
FT                                NFKBIA; when associated with A-143; A-
FT                                147; A-149 and A-150.
FT                                {ECO:0000269|PubMed:17698585}.
FT   MUTAGEN     203    203       S->A: Abolishes phosphorylation by CK2.
FT                                Impairs nuclear localization; when
FT                                associated with A-222; A-231; A-233 and
FT                                A-236. {ECO:0000269|PubMed:11546811}.
FT   MUTAGEN     222    222       S->A: Abolishes phosphorylation by CK2.
FT                                Impairs nuclear localization; when
FT                                associated with A-203; A-231; A-233 and
FT                                A-236. {ECO:0000269|PubMed:11546811}.
FT   MUTAGEN     231    231       S->A: Abolishes phosphorylation by CK2.
FT                                Impairs nuclear localization; when
FT                                associated with A-203; A-222; A-233 and
FT                                A-236. {ECO:0000269|PubMed:11546811,
FT                                ECO:0000269|PubMed:12037680}.
FT   MUTAGEN     233    233       T->A: Abolishes phosphorylation by CK2.
FT                                Impairs nuclear localization; when
FT                                associated with A-203; A-222; A-231 and
FT                                A-236. {ECO:0000269|PubMed:11546811}.
FT   MUTAGEN     236    236       S->A: Abolishes phosphorylation by CK2.
FT                                Impairs nuclear localization; when
FT                                associated with A-203; A-222; A-231 and
FT                                A-233. {ECO:0000269|PubMed:11546811}.
FT   HELIX         8     22       {ECO:0000244|PDB:3RZ3}.
FT   STRAND       28     32       {ECO:0000244|PDB:3RZ3}.
FT   STRAND       40     46       {ECO:0000244|PDB:3RZ3}.
FT   TURN         52     55       {ECO:0000244|PDB:3RZ3}.
FT   STRAND       57     63       {ECO:0000244|PDB:3RZ3}.
FT   TURN         66     69       {ECO:0000244|PDB:3RZ3}.
FT   STRAND       74     79       {ECO:0000244|PDB:3RZ3}.
FT   STRAND       90     92       {ECO:0000244|PDB:3RZ3}.
FT   HELIX        94     97       {ECO:0000244|PDB:2OB4}.
FT   HELIX       120    132       {ECO:0000244|PDB:3RZ3}.
FT   HELIX       142    153       {ECO:0000244|PDB:3RZ3}.
FT   TURN        154    156       {ECO:0000244|PDB:3RZ3}.
FT   HELIX       160    178       {ECO:0000244|PDB:3RZ3}.
SQ   SEQUENCE   236 AA;  26737 MW;  258960666B589DB3 CRC64;
     MARPLVPSSQ KALLLELKGL QEEPVEGFRV TLVDEGDLYN WEVAIFGPPN TYYEGGYFKA
     RLKFPIDYPY SPPAFRFLTK MWHPNIYETG DVCISILHPP VDDPQSGELP SERWNPTQNV
     RTILLSVISL LNEPNTFSPA NVDASVMYRK WKESKGKDRE YTDIIRKQVL GTKVDAERDG
     VKVPTTLAEY CVKTKAPAPD EGSDLFYDDY YEDGEVEEEA DSCFGDDEDD SGTEES
//
